| Ident. | Authors (with country if any) | Title |
|---|
| 000063 (2012) |
Gregory L. Willis [Australie] ; Cleo Moore [Australie] ; Stuart M. Armstrong [Australie] | Breaking away from dopamine deficiency: an essential new direction for Parkinson’s disease |
| 000113 (2011) |
István Sziklai [Hongrie] ; Judit Szilvássy [Hongrie] ; Zoltán Szilvássy [Hongrie] | Tinnitus control by dopamine agonist pramipexole in presbycusis patients: A randomized, placebo‐controlled, double‐blind study |
| 000117 (2011) |
Vibeke Guldbrand Rasmussen [Danemark] ; Karen Stergaard [Danemark] ; Erik Dupont [Danemark] ; Steen Hvitfeldt Poulsen [Danemark] | The risk of valvular regurgitation in patients with Parkinson's disease treated with dopamine receptor agonists |
| 000159 (2011) |
Keisuke Matsubara [Japon] ; Hiroshi Watabe [Japon] ; Yoshitaka Kumakura [Japon] ; Takuya Hayashi [Japon] ; Christopher J. Endres [États-Unis] ; Kotaro Minato [Japon] ; Hidehiro Iida [Japon] | Sensitivity of kinetic macro parameters to changes in dopamine synthesis, storage, and metabolism: A simulation study for [18F]FDOPA PET by a model with detailed dopamine pathway |
| 000291 (2011) |
Polly Ambermoon [Australie] ; Adrian Carter [Australie] ; Wayne D. Hall [Australie] ; Nadeeka N. W. Dissanayaka [Australie] ; John D. O'Sullivan [Australie] | Impulse control disorders in patients with Parkinson's disease receiving dopamine replacement therapy: evidence and implications for the addictions field |
| 000293 (2011) |
D. Okai [Royaume-Uni] ; M. Samuel ; S. Askey-Jones [Royaume-Uni] ; A. S. David [Royaume-Uni] ; R. G. Brown [Royaume-Uni] | Impulse control disorders and dopamine dysregulation in Parkinson’s disease: a broader conceptual framework |
| 000337 (2011) |
Thomas D. H Lbig [États-Unis, Allemagne] ; Stephanie Assuras [États-Unis] ; Judy Creighton [États-Unis] ; Joan C. Borod [États-Unis] ; Winona Tse [États-Unis] ; Pasquale G. Frisina [États-Unis] ; Andrei Voustianiouk [États-Unis] ; Jean-Michel Gracies [États-Unis] ; C. Warren Olanow [États-Unis] | Differential role of dopamine in emotional attention and memory: Evidence from Parkinson's disease |
| 000628 (2010) |
P. Barone [Italie] | Neurotransmission in Parkinson’s disease: beyond dopamine |
| 000724 (2010) |
Marta G. Vu Ckovi [États-Unis] ; Quanzheng Li [États-Unis] ; Beth Fisher [États-Unis] ; Angelo Nacca [États-Unis] ; Richard M. Leahy [États-Unis] ; John P. Walsh [États-Unis] ; Jogesh Mukherjee [États-Unis] ; Celia Williams [États-Unis] ; Michael W. Jakowec [États-Unis] ; Giselle M. Petzinger [États-Unis] | Exercise elevates dopamine D2 receptor in a mouse model of Parkinson's disease: In vivo imaging with [18F]fallypride |
| 000738 (2010) |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas] | Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease |
| 000739 (2010) |
Jeff A. Beeler [États-Unis] ; Zhen Fang Huang Cao [États-Unis] ; Mazen A. Kheirbek [États-Unis] ; Yunmin Ding [États-Unis] ; Jessica Koranda [États-Unis] ; Mari Murakami [États-Unis] ; Un Jung Kang [États-Unis] ; Xiaoxi Zhuang [États-Unis] | Dopamine‐dependent motor learning: Insight into levodopa's long‐duration response |
| 000742 (2010) |
Vesna Sossi [Canada] ; Raul De La Fuente-Fernández [Canada] ; Ramachandiran Nandhagopal [Canada] ; Michael Schulzer [Canada] ; Jessamyn Mckenzie [Canada] ; Thomas J. Ruth [Canada] ; Jan O. Aasly [Norvège] ; Matthew J. Farrer [États-Unis] ; Zbigniew K. Wszolek [États-Unis] ; Jon A. Stoessl [Canada] | Dopamine turnover increases in asymptomatic LRRK2 mutations carriers |
| 000809 (2010) |
Petra Schwingenschuh [Royaume-Uni, Autriche] ; Petra Katschnig [Royaume-Uni, Autriche] ; Ronald Saurugg [Autriche] ; Erwin Ott [Autriche] ; Kailash P. Bhatia [Royaume-Uni] | Artistic profession: A potential risk factor for dopamine dysregulation syndrome in Parkinson's disease? |
| 000840 (2010) |
C. Savio Chan [États-Unis] ; Tracy S. Gertler [États-Unis] ; D. James Surmeier [États-Unis] | A molecular basis for the increased vulnerability of substantia nigra dopamine neurons in aging and Parkinson's disease |
| 000926 (2009) |
Chen [États-Unis] ; Swope [États-Unis] ; Dashtipour [États-Unis] ; Lyons [États-Unis] | Transdermal Rotigotine: A Clinically Innovative Dopamine‐Receptor Agonist for the Management of Parkinson's Disease |
| 000A22 (2009) |
Shin-Ichi Muramatsu [Japon] ; Tsuyoshi Okuno [Japon] ; Yutaka Suzuki [Japon] ; Takashi Nakayama [Japon] ; Takeharu Kakiuchi [Japon] ; Naomi Takino [Japon] ; Asako Iida [Japon] ; Fumiko Ono [Japon] ; Keiji Terao [Japon] ; Nobuo Inoue [Japon] ; Imaharu Nakano [Japon] ; Yasushi Kondo [Japon] ; Hideo Tsukada [Japon] | Multitracer assessment of dopamine function after transplantation of embryonic stem cell‐derived neural stem cells in a primate model of Parkinson's disease |
| 000B10 (2009) |
Rogan B. Tinsley [Australie] ; Chris R. Bye [Australie] ; Clare L. Parish [Australie] ; Angela Tziotis-Vais [Australie] ; Sonia George [Australie] ; Janetta G. Culvenor [Australie] ; Qiao-Xin Li [Australie] ; Colin L. Masters [Australie] ; David I. Finkelstein [Australie] ; Malcolm K. Horne [Australie] | Dopamine D2 receptor knockout mice develop features of Parkinson disease |
| 000B28 (2009) |
Zhen Qi [États-Unis] ; Gary W. Miller [États-Unis] ; Eberhard O. Voit [États-Unis] | Computational analysis of determinants of dopamine (DA) dysfunction in DA nerve terminals |
| 000B48 (2009) |
Frank Andersohn [Allemagne] ; Edeltraut Garbe [Allemagne] | Cardiac and noncardiac fibrotic reactions caused by ergot‐and nonergot‐derived dopamine agonists |
| 000B73 (2009) |
R. Talati [États-Unis] ; W. L. Baker [États-Unis] ; A. A. Patel [États-Unis] ; K. Reinhart [États-Unis] ; C. I. Coleman [États-Unis] | Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson’s disease: a meta analysis |
| 000C45 (2008) |
Stanley Fahn [États-Unis] | The history of dopamine and levodopa in the treatment of Parkinson's disease |
| 000C65 (2008) |
Irena Rektorova [République tchèque] ; Hana Srovnalova [République tchèque] ; Radka Kubikova [République tchèque] ; Jiri Prasek [République tchèque] | Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease |
| 000C66 (2008) |
Yoland Smith [États-Unis] ; Rosa Villalba [États-Unis] | Striatal and extrastriatal dopamine in the basal ganglia: An overview of its anatomical organization in normal and Parkinsonian brains |
| 000C94 (2008) |
Eleonora Bazzini [Italie] ; Alberta Samuele [Italie] ; Marcella Granelli [Italie] ; Giovanna Levandis [Italie] ; Marie-Therese Armentero [Italie] ; Giuseppe Nappi [Italie] ; Fabio Blandini [Italie] | Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: The synergistic role of dopamine |
| 000D10 (2008) |
Asmar F. Al Hadithy [Pays-Bas] ; Bob Wilffert [Pays-Bas] ; Roy E. Stewart [Pays-Bas] ; Nicole M. Looman [Pays-Bas] ; Richard Bruggeman [Pays-Bas] ; Jacobus R. Brouwers [Pays-Bas] ; Glenn E. Matroos [Pays-Bas] ; Jim Van Os [Pays-Bas] ; Hans W. Hoek [Pays-Bas] ; Peter N. Van Harten [Pays-Bas] | Pharmacogenetics of parkinsonism, rigidity, rest tremor, and bradykinesia in African‐Caribbean inpatients: Differences in association with dopamine and serotonin receptors |
| 000D52 (2008) |
Chun-Hung Lin ; Jui-Yen Huang [Taïwan] ; Cheng-Hsin Ching ; Jih-Ing Chuang [Taïwan] | Melatonin reduces the neuronal loss, downregulation of dopamine transporter, and upregulation of D2 receptor in rotenone‐induced parkinsonian rats |
| 000D61 (2008) |
C. Warren Olanow [États-Unis] | Levodopa/dopamine replacement strategies in Parkinson's disease—Future directions |
| 000E15 (2008) |
Masaki Wakamatsu [Japon] ; Shingo Iwata [Japon] ; Takeo Funakoshi [Japon] ; Makoto Yoshimoto [Japon] | Dopamine receptor agonists reverse behavioral abnormalities of α‐synuclein transgenic mouse, a new model of Parkinson's disease |
| 000E16 (2008) |
Daniel Weintraub [États-Unis] | Dopamine and impulse control disorders in Parkinson's disease |
| 000E45 (2008) |
J. C. Möller [Allemagne] ; K. M. Eggert [Allemagne] ; M. Unger [Allemagne] ; P. Odin [Allemagne] ; K. R. Chaudhuri [Royaume-Uni] ; W. H. Oertel [Allemagne] | Clinical risk–benefit assessment of dopamine agonists |
| 000E66 (2008) |
Virginie Czernecki [France] ; Michael Schüpbach [France, Suisse] ; Sadek Yaici [France] ; Richard Lévy [France] ; Eric Bardinet [France] ; Jérôme Yelnik [France] ; Bruno Dubois [France] ; Yves Agid [France] | Apathy following subthalamic stimulation in Parkinson disease: A dopamine responsive symptom |
| 000F57 (2007) |
Margaret A. Piggott [Royaume-Uni] ; Clive G. Ballard [Royaume-Uni] ; Elise Rowan [Royaume-Uni] ; Clive Holmes [Royaume-Uni] ; Ian G. Mckeith [Royaume-Uni] ; Evelyn Jaros [Royaume-Uni] ; Robert H. Perry [Royaume-Uni] ; Elaine K. Perry [Royaume-Uni] | Selective loss of dopamine D2 receptors in temporal cortex in dementia with Lewy bodies, association with cognitive decline |
| 000F72 (2007) |
Timothy M. Fountaine [Royaume-Uni] ; Richard Wade-Martins [Royaume-Uni] | RNA interference‐mediated knockdown of α‐synuclein protects human dopaminergic neuroblastoma cells from MPP+ toxicity and reduces dopamine transport |
| 000F90 (2007) |
David A. Gallagher [Royaume-Uni] ; Sean S. O'Sullivan [Royaume-Uni] ; Andrew H. Evans [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Anette Schrag [Royaume-Uni] | Pathological gambling in Parkinson's disease: Risk factors and differences from dopamine dysregulation. An analysis of published case series |
| 001014 (2007) |
Gregor Simonis [Allemagne] ; Joerg T. Fuhrmann [Allemagne] ; Ruth H. Strasser [Allemagne] | Meta‐analysis of heart valve abnormalities in Parkinson's disease patients treated with dopamine agonists |
| 001040 (2007) |
Emilie Lacombe ; Carole Carcenac ; Sabrina Boulet ; Claude Feuerstein [France] ; Anne Bertrand ; Annie Poupard ; Marc Savasta [France] | High‐frequency stimulation of the subthalamic nucleus prolongs the increase in striatal dopamine induced by acute l‐3,4‐dihydroxyphenylalanine in dopaminergic denervated rats |
| 001069 (2007) |
Vesna Sossi [Canada] ; Raúl De La Fuente-Fernández [Espagne] ; Michael Schulzer [Canada] ; Andre R. Troiano [Canada] ; Thomas J. Ruth [Canada] ; A. Jon Stoessl [Canada] | Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study |
| 001071 (2007) |
Soon S. Park [États-Unis] ; Emily M. Schulz [États-Unis] ; Daewoo Lee [États-Unis] | Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by α‐synuclein |
| 001167 (2006) |
Ji-Youn Kim [Corée du Sud] ; Eun Joo Chung [Corée du Sud] ; Seung Woo Park [Corée du Sud] ; Won Yong Lee [Corée du Sud] | Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists |
| 001196 (2006) |
Ioannis U. Isaias [Italie] ; Riccardo Benti [Italie] ; Stefano Goldwurm [Italie] ; Michela Zini [Italie] ; Roberto Cilia [Italie] ; Paolo Gerundini [Italie] ; Alessio Di Fonzo [Pays-Bas, Italie] ; Vincenzo Bonifati [Pays-Bas, Italie] ; Gianni Pezzoli [Italie] ; Angelo Antonini [Italie] | Striatal dopamine transporter binding in Parkinson's disease associated with the LRRK2 Gly2019Ser mutation |
| 001315 (2006) |
Daniel Oved [Israël] ; Ilan Ziv [Israël] ; Therese A. Treves [Israël] ; Diana Paleacu [Israël] ; Eldad Melamed [Israël] ; Ruth Djaldetti [Israël] | Effect of dopamine agonists on fatigue and somnolence in Parkinson's disease |
| 001332 (2006) |
Andrew H. Evans [Royaume-Uni] ; Nicola Pavese [Royaume-Uni] ; Andrew D. Lawrence [Royaume-Uni] ; Yen F. Tai [Royaume-Uni] ; Silke Appel [Royaume-Uni] ; Miroslava Doder [Royaume-Uni] ; David J. Brooks [Royaume-Uni] ; Andrew Lees (neurologue) [Royaume-Uni] ; Paola Piccini [Royaume-Uni] | Compulsive drug use linked to sensitized ventral striatal dopamine transmission |
| 001362 (2006) |
Rebecca E. Colebrooke [Royaume-Uni] ; Trevor Humby [Royaume-Uni] ; Patrick J. Lynch [Royaume-Uni] ; Daniel P. Mcgowan [Royaume-Uni] ; Jing Xia [Royaume-Uni] ; Piers C. Emson [Royaume-Uni] | Age‐related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson's disease |
| 001428 (2005) |
Katherine L. Widnell [États-Unis] ; Cynthia Comella [États-Unis] | Role of COMT inhibitors and dopamine agonists in the treatment of motor fluctuations |
| 001467 (2005) |
Yasuomi Ouchi ; Etsuji Yoshikawa [Japon] ; Yoshimoto Sekine [Japon] ; Masami Futatsubashi [Japon] ; Toshihiko Kanno ; Tomomi Ogusu [Japon] ; Tatsuo Torizuka | Microglial activation and dopamine terminal loss in early Parkinson's disease |
| 001506 (2005) |
Fang Du [République populaire de Chine] ; Rui Li [République populaire de Chine] ; Yuangui Huang [République populaire de Chine] ; Xuping Li [République populaire de Chine] ; Weidong Le [République populaire de Chine] | Dopamine D3 receptor‐preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons |
| 001509 (2005) |
Philippe Remy [France] ; Miroslava Doder [France] ; Andrew Lees (neurologue) [Royaume-Uni, France] ; Nora Turjanski [France] ; David Brooks [France] | Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system |
| 001518 (2005) |
K. Stiasny-Kolster ; Y. Doerr ; J. C. Mo Ller ; H. Ho Ffken ; T. M. Behr ; W. H. Oertel ; G. Mayer [Allemagne] | Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for α-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT |
| 001527 (2005) |
J. Eric Ahlskog [États-Unis] | Challenging conventional wisdom: The etiologic role of dopamine oxidative stress in Parkinson's disease |
| 001560 (2004) |
Anthony E. Lang [Canada] ; José A. Obeso [Espagne] | Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease |
| 001566 (2004) |
John G. Nutt [États-Unis] ; Julie H. Carter [États-Unis] ; Gary J. Sexton [États-Unis] | The dopamine transporter: Importance in Parkinson's disease |
